NGM NASDAQ
NGM Biopharmaceuticals, Inc.
1W: -1.3%
1M: +0.7%
3M: +14.9%
1Y: -60.8%
3Y: -94.5%
5Y: -89.5%
$1.54
Last traded 2024-04-08 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$4M
-92.0% ▼
5Y CAGR: -47.3%
Gross Profit
$2M
-95.6% ▼
5Y CAGR: -54.2%
Operating Income
-$147M
+11.9% ▲
Net Income
-$142M
+10.5% ▲
EPS (Diluted)
$-1.73
+13.1% ▲
EBITDA
-$144M
+13.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $104M | $87M | $78M | $55M | $4M |
| YoY Growth | -4.7% | -15.6% | -10.9% | -29.0% | -92.0% |
| Cost of Revenue | $129M | $164M | $8M | $6M | $2M |
| Gross Profit | -$26M | -$77M | $70M | $49M | $2M |
| Gross Margin | -24.8% | -87.7% | 89.9% | 89.2% | 49.7% |
| R&D Expenses | $129M | $164M | $162M | $181M | $112M |
| SG&A Expenses | $24M | $27M | $37M | $41M | $37M |
| Operating Expenses | $153M | $191M | $199M | $222M | $149M |
| Operating Income | -$49M | -$104M | -$121M | -$166M | -$147M |
| Operating Margin | -47.7% | -118.8% | -155.0% | -300.5% | -3317.8% |
| Interest Expense | $0 | $0 | $0 | $4M | $0 |
| Income Before Tax | -$43M | -$102M | -$120M | -$163M | -$142M |
| Tax Expense | -$14M | -$8M | -$7M | -$4M | $0 |
| Net Income | -$28M | -$94M | -$114M | -$159M | -$142M |
| Net Margin | -27.5% | -107.6% | -146.2% | -287.5% | -3223.3% |
| EPS (Diluted) | $-0.57 | $-1.37 | $-1.48 | $-1.99 | $-1.73 |
| EBITDA | -$49M | -$104M | -$121M | -$155M | -$144M |
| Shares Outstanding | 50M | 68M | 77M | 80M | 82M |